A detailed history of Jim Simons (Renaissance Technologies LLC) transactions in Relay Therapeutics, Inc. stock. As of the latest transaction made, Renaissance Technologies LLC holds 671,095 shares of RLAY stock, worth $2.93 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
671,095
Previous 909,037 26.18%
Holding current value
$2.93 Million
Previous $5.93 Million 19.83%
% of portfolio
0.01%
Previous 0.01%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$6.23 - $9.51 $1.48 Million - $2.26 Million
-237,942 Reduced 26.18%
671,095 $4.75 Million
Q2 2024

Aug 09, 2024

BUY
$5.9 - $8.02 $860,438 - $1.17 Million
145,837 Added 19.11%
909,037 $5.93 Million
Q1 2024

May 13, 2024

BUY
$7.5 - $12.07 $3.3 Million - $5.3 Million
439,500 Added 135.77%
763,200 $6.34 Million
Q4 2023

Feb 13, 2024

BUY
$6.01 - $11.48 $1.08 Million - $2.05 Million
179,000 Added 123.7%
323,700 $3.56 Million
Q3 2023

Nov 14, 2023

BUY
$8.24 - $12.97 $1.19 Million - $1.88 Million
144,700 New
144,700 $1.22 Million
Q1 2023

May 12, 2023

BUY
$15.0 - $22.76 $870,810 - $1.32 Million
58,054 Added 95.48%
118,854 $1.96 Million
Q4 2022

Feb 13, 2023

BUY
$14.16 - $24.02 $860,928 - $1.46 Million
60,800 New
60,800 $908,000
Q2 2022

Aug 12, 2022

SELL
$13.31 - $34.88 $25,289 - $66,272
-1,900 Reduced 6.83%
25,900 $434,000
Q1 2022

May 13, 2022

BUY
$20.26 - $32.36 $421,408 - $673,088
20,800 Added 297.14%
27,800 $832,000
Q4 2021

Feb 11, 2022

SELL
$26.0 - $37.03 $3.79 Million - $5.39 Million
-145,588 Reduced 95.41%
7,000 $215,000
Q3 2021

Nov 12, 2021

BUY
$29.75 - $37.99 $4.54 Million - $5.8 Million
152,588 New
152,588 $4.81 Million

Others Institutions Holding RLAY

About Relay Therapeutics, Inc.


  • Ticker RLAY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 120,219,000
  • Market Cap $524M
  • Description
  • Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhib...
More about RLAY
Track Jim Simons's Portfolio

Track Jim Simons Portfolio

Follow Jim Simons (Renaissance Technologies LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.